Biggest News Aggregation in the World
📰 Divi Lab News

Page 8 - Divi Lab News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Divi Lab. Real-time updates on events, politics, business and more.

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Nifty: Go for wealth management cos, not AMCs; cyclical upswing in auto: Dipan Mehta

“A 8-9% volume growth is enough to generate a 15-16% type of a top line growth in terms of revenues and that could lead to 20% type of a growth at the profit level. That is keeping a lot of players interested in the auto industry. These are mildly cyclical businesses as well. We are seeing a good cyclical upswing in the auto industry.”
Dipan Mehta Divi Lab Elixir Equities Anand Rathi Wealth Mankind Pharma

stocks to buy: Chart Check: After 30% rally from 52-week low, this pharma stock could retest Rs 3,900 levels; time to buy?

Divis Laboratories, a pharmaceutical company, has seen a rally of over 30% since March 2023. The stock has surpassed key moving averages and the chart pattern suggests that the rally may continue. Experts suggest that short-term traders could buy the stock, with a possible target above Rs 3,900 in the next 3-4 weeks. The stock has found support above Rs 3,000 and is trading above various moving averages. The Relative Strength Index (RSI) is at 59.6, indicating bullish momentum.
Kiran Jani Head Of Technical Research At Jainam Broking Divi Lab Relative Strength Index Technical Research Jainam Broking

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science